FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer

Table 2 Phase III clinical trials with new targeted anticancer agents combined with gemcitabine-based chemotherapy in metastatic pancreatic cancer patients

Ref.	Treatment arms	Patients	Results
Kindler et al[69] J Clin Oncol 2010	Gemcitabine + bevacizumab vs gemcitabine + placebo	302	OS: 5.8 mo vs 5.9 mo (P = 0.95)
			PFS: 3.8 mo vs 2.9 mo (P = 0.07)
		300	RR: 13% vs 10% (P = NR)
Van Cutsem et al[70] J Clin Oncol 2009	Erlotinib + gemcitabine + bevacizumab vs erlotinib + gemcitabine + placebo	306	OS: 7.1 mo vs 6.0 mo (P = 0.2087)
			PFS: 4.6 mo vs 3.6 mo (P = 0.0002)
		301	RR: 13.5% vs 8.6% (P = 0.0574)
Rougier et al[71] Eur J Cancer 2013	Gemcitabine + aflibercept vs gemcitabine + placebo	271	OS: 6.5 mo vs 7.8 mo (P = 0.2034)
			PFS: 3.7 mo vs 3.7 mo (P = 0.8645)
		275	RR: NR
Kindler et al[73] Lancet Oncol 2011	Gemcitabine + axitinib vs gemcitabine + placebo	316	OS: 8.5 mo vs 8.3 mo (P = 0.5436)
			PFS: 4.4 mo vs 4.4 mo (P = 0.5203)
		316	RR: 5% vs 2% (P = 0.0180)
Gonçalves et al[74] Ann Oncol 2012	Gemcitabine + sorafenib vs gemcitabine + placebo	52	OS: 8.0 mo vs 9.2 mo (P = 0.231)
			PFS: 3.8 mo vs 5.7 mo (P = 0.902)
		52	RR: 23% vs 19% (P = NR)
Philip et al[94] J Clin Oncol 2010	Gemcitabine + cetuximab vs gemcitabine	372	OS: 6.3 mo vs 5.9 mo (P = 0.19)
			PFS: 3.4 mo vs 3.0 mo (P = 0.18)
		371	RR: 14% vs 12% (P = 0.59)

OS: Overall survival; PFS: Progression free survival; RR: Response rate; NR: Not reported.